For patients with germline BRCA1/2 mutations, how do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies?

For patients with BRCA 1/2 germline mutations, how do you navigate the conversation with patients regarding the potential risks of RT exposure and secondary malignancies?

Answer from: Medical Oncologist at Academic Institution

I believe that the benefit of breast and regional nodal irradiation in terms of reducing the risk of local or regional recurrence typically outweighs the risk of secondary breast or soft tissue malignancies, though I might favor omitting this treatment in a patient with likely marginal benefit from ...

Please select the option that best describes you:

For patients with germline BRCA1/2 mutations, how do you approach the discussion about the potential risks of radiation therapy exposure and the development of secondary malignancies?

Related Questions